TABLE 1.

Neutralization of HPIV3 and HPIV3/EboGP with anti-HPIV3 and/or anti-EV antibodies

Virus	Cells	Antibody dilution	Amt of infectious virus (log10 PFU) following neutralization witha:
			Anti-HPIV3	Anti-EV	Anti-HPIV3 + anti-EV
HPIV3	LLC-MK2	1:10	<1.2	3.9	<1.2
		1:40	<1.2	NDb	<1.2
		No antibody	4.7	4.6	4.6
	Vero	1:10	<1.2	3.9	<1.2
		1:40	<1.2	ND	<1.2
		No antibody	4.8	4.8	4.7
HPIV3/EboGP	LLC-MK2	1:10	3.2	<1.2	1.2
		1:40	3.7	2.1	2.6
		No antibody	4.7	4.7	4.7
	Vero	1:10	3.6	1.7	1.9
		1:40	3.9	2.3	2.7
		No antibody	4.9	5.1	5.2

^aThe indicated viruses (10^5.2 PFU) were incubated with the indicated dilution of anti-HPIV3 antibodies, anti-EV antibodies, or their mixture in the presence of complement. After the incubation, the residual infectivity was determined on day 7 by plaque titration in the indicated cell lines.

^bND, not determined.